No price history available.
Key financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | TWDm | 2,347 | 2,573 | 3,161 | 3,930 | 4,653 | 5,655 | 5,845 | N/A |
| Operating profit | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | TWDm | 102 | 52 | 222 | 384 | 456 | 562 | 460 | N/A |
| EPS reported | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
United Orthopedic Corporation is a firm dedicated to the research, development, manufacturing, and global distribution of advanced orthopedic implants and specialized surgical instruments. The company's extensive product offerings address a wide spectrum of orthopedic needs. Its comprehensive range of hip and knee solutions includes various artificial hip joints, partial hip replacements, specialized joints for large trochanteric fractures, and Moore hip prostheses. Uniquely, it also designs and supplies custom artificial hip and knee joints specifically tailored for individual tumor patients, alongside standard artificial knee replacement joints, revision systems, and restricted artificial knee joints. For spinal care, United Orthopedic manufactures vertebral fixation devices. Furthermore, its portfolio extends to injury and trauma products, which encompass a variety of orthopedic internal fixation items, bone plates, bone nails, bone pins, and bone screws. The company also functions as an OEM supplier for orthopedic internal fixation solutions and provides specialized lamb salvage systems. Beyond implants, United Orthopedic Corporation delivers orthopedic surgical equipment and the machinery necessary for its manufacturing. It also trades in special metal and plastic materials, actively engaging in the import and export of its products across international markets. With a global footprint, the company conducts business in Taiwan, across Asia, the Americas, Europe, Africa, and Australia. Established in 1993, United Orthopedic Corporation is headquartered in New Taipei City, Taiwan, and operates as a subsidiary of Chi-Yi Investment Co. Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
United Orthopedic Corporation (4129.TWO)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
United Orthopedic Corporation is a firm dedicated to the research, development, manufacturing, and global distribution of advanced orthopedic implants and specialized surgical instruments. The company's extensive product offerings address a wide spectrum of orthopedic needs. Its comprehensive range of hip and knee solutions includes various artificial hip joints, partial hip replacements, specialized joints for large trochanteric fractures, and Moore hip prostheses. Uniquely, it also designs and supplies custom artificial hip and knee joints specifically tailored for individual tumor patients, alongside standard artificial knee replacement joints, revision systems, and restricted artificial knee joints. For spinal care, United Orthopedic manufactures vertebral fixation devices. Furthermore, its portfolio extends to injury and trauma products, which encompass a variety of orthopedic internal fixation items, bone plates, bone nails, bone pins, and bone screws. The company also functions as an OEM supplier for orthopedic internal fixation solutions and provides specialized lamb salvage systems. Beyond implants, United Orthopedic Corporation delivers orthopedic surgical equipment and the machinery necessary for its manufacturing. It also trades in special metal and plastic materials, actively engaging in the import and export of its products across international markets. With a global footprint, the company conducts business in Taiwan, across Asia, the Americas, Europe, Africa, and Australia. Established in 1993, United Orthopedic Corporation is headquartered in New Taipei City, Taiwan, and operates as a subsidiary of Chi-Yi Investment Co. Ltd.
